Trial · NCT02750514
Results by group119
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 119
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | Nivolumab | Study Track 1 | 17.5 | 95% Confidence Interval 7.3 to 32.8 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + Dasatinib | Study Track 1 | 25.0 | 95% Confidence Interval 0.6 to 80.6 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + Ipilimumab | Study Track 1 | 0 | 95% Confidence Interval 0.0 to 70.8 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab | Study Track 2 | 0 | 95% Confidence Interval 0.0 to 33.6 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + Dasatinib | Study Track 2 | 0 | 95% Confidence Interval 0.0 to 33.6 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + BMS986016 | Study Track 2 | 0 | 95% Confidence Interval 0.0 to 84.2 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + Ipilimumab | Study Track 2 | 25.0 | 95% Confidence Interval 5.5 to 57.2 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + Dasatinib | Study Track 3 | 2.4 | 95% Confidence Interval 0.1 to 12.9 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + BMS986016 | Study Track 3 | 0 | 95% Confidence Interval 0.0 to 20.6 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + Ipilimumab | Study Track 3 | 5.6 | 95% Confidence Interval 0.1 to 27.3 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + Dasatinib | Study Track 4 | 1.9 | 95% Confidence Interval 0.0 to 10.1 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + Ipilimumab | Study Track 4 | 20.0 | 95% Confidence Interval 10.8 to 32.3 | Percent of Participants |
| Objective Response Rate (ORR) | Nivolumab + BMS986205 | Study Track 5 | 2.3 | 95% Confidence Interval 0.1 to 12.3 | Percent of Participants |
| Duration of Response (DOR) | Nivolumab | Study Track 1 | 12.81 | 95% Confidence Interval 0.0 to NA | Months |
| Duration of Response (DOR) | Nivolumab + Dasatinib | Study Track 1 | 8.57 | 95% Confidence Interval NA to NA | Months |
| Duration of Response (DOR) | Nivolumab + Ipilimumab | Study Track 2 | NA | 95% Confidence Interval NA to NA | Months |
| Duration of Response (DOR) | Nivolumab + Dasatinib | Study Track 3 | NA | 95% Confidence Interval NA to NA | Months |
| Duration of Response (DOR) | Nivolumab + Ipilimumab | Study Track 3 | NA | 95% Confidence Interval NA to NA | Months |
| Duration of Response (DOR) | Nivolumab + Dasatinib | Study Track 4 | NA | 95% Confidence Interval NA to NA | Months |
| Duration of Response (DOR) | Nivolumab + Ipilimumab | Study Track 4 | 12.65 | 95% Confidence Interval 8.7 to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02750514/results